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Introduction
Embryogenesis is regulated by a number of complex sig-
naling cascades, which are critical for normal develop-
ment. One such pathway begins with a secreted protein
called “SONIC HEDGEHOG” (SHH [MIM 600725]),
which sets off a chain of events in target cells, leading
to the activation and repression of target genes by tran-
scription factors in the Gli family. Dysregulation of the
Sonic hedgehog–Patched–Gli (Shh-Ptch-Gli) pathway
leads to several human diseases, including birth defects
and cancers.
Elements of the Shh-Ptch-Gli pathway are highly con-
served, indicating its essential role in development.
However, Shh signaling is also apparently susceptible
to evolutionary pressures. Thus, Shh signaling has been
adapted to serve tremendously diverse functions in a
wide array of animal models, in both embryonic and
adult life. Shh and the downstream molecules involved
in signal transduction vary, to some extent, between
animals, as well. Although a great deal can be learned
from the study of animal models, it is essential to not
assume that what is true in one model system is nec-
essarily true in another. Thus, this review focuses spe-
cifically on our current understanding of the Shh-Ptch-
Gli pathway and its clinical significance in humans.
The Human SHH-PTCH-GLI Signaling Pathway
During the past few years, a great deal of information
about the mechanisms and significance of human SHH-
PTCH-GLI signaling has emerged. SHH induces cell
proliferation in a tissue-specific manner during embry-
ogenesis, and inherited or sporadic mutations in SHH-
pathway genes have been implicated in a number of
human birth defects. If the SHH-PTCH-GLI pathway is
aberrantly activated during adult life, the resulting cel-
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lular proliferation manifests as cancer. Thus, studying
the human SHH-PTCH-GLI pathway is essential in the
understanding of the mechanisms of human birth defects
and cancer and, ultimately, in the identification thera-
peutic targets in SHH-pathway diseases.
Our current understanding of the human SHH-
PTCH-GLI pathway and its role in human disease is
outlined in figure 1. Since the Shh-pathway components,
their tissue specificity, and their functions vary between
species (Lee et al. 1997; Sasaki et al. 1997; Brewster et
al. 1998; Keys et al. 1999; King and Brown 1999), only
information from human genes and proteins is pre-
sented here. Interestingly, defects in any of several steps
in the SHH-PTCH-GLI pathway lead to similar clinical
phenotypes, presumably through functionally equiva-
lent effects on downstream target genes.
Sonic Hedgehog
During development of the human embryo, SONIC
HEDGEHOG (SHH) is expressed in the notochord, the
floorplate of the neural tube, the brain, the zone of po-
larizing activity in the developing limbs, and the gut
(Odent et al. 1999). The tissue-specific expression of other
SHH-pathway members has not yet been determined in
human embryogenesis, although GLI1 (MIM 165220),
GLI2 (MIM 165230), and GLI3 (MIM 165240) RNA
expression is known to persist in some adult human tis-
sues (Ruppert et al. 1988). Sporadic and inherited mu-
tations in the human SHH gene have been shown to cause
holoprosencephaly (HPE [MIM 236100]), a severe mid-
line defect that includes cleft lip and palate, single max-
illary incisor, impaired CNS septation, and phenotypes
ranging in severity from hypotelorism to a single cyclopic
eye (Belloni et al. 1996; Roessler et al. 1996, 1997; Nanni
et al. 1999). HPE is a frequent cause of prenatal death
in humans; it is detected in 1/250 induced abortions but
in only 1/16,000 live births (Cohen 1989).
The SHH protein needs to be processed to an active
form in order to function in developmental patterning.
SHH is cleaved to an active N-terminal form, which is
then modified by the addition of a cholesterol moiety
(Pepinsky et al. 1998; Williams et al. 1999). Defects in
cholesterol biosynthesis lead to the autosomal recessive
1048 Am. J. Hum. Genet. 67:1047–1054, 2000
Figure 1 Human SHH-PTCH-GLI pathway (left) and its links to human diseases (right). The association of the human disease withmalfunction
of a given element in the pathway is indicated by the matching colors of the boxes. The placement of the elements of the pathway, as well as their
role as a repressor (bars) or as an activator (arrows), has been demonstrated in humans. The exceptions are that interaction between human GLI3
and CBP was demonstrated using mouse CBP (Dai et al. 1999), human GLI genes were tested in frog and mouse cells (Ruiz i Altaba 1998; Dai
et al. 1999), and mouse gli2 protein function is shown for completeness, although human GLI2 has not been fully characterized (Tanimura et al.
1998; Sasaki et al. 1999).
Smith-Lemli-Opitz (SLOS [MIM 270400]) syndrome
in humans, which shares some features with SHH-path-
way diseases. This suggests that some or all of the clin-
ical features of SLOS may be due to defective SHH
signaling (Donnai et al. 1987; Tint et al. 1994; Kelley
et al. 1996). Patients with SLOS generally have syn-
dactyly, anteverted nares, ptosis, cryptorchidism, CNS
hypoplasia, failure to thrive, occasional polydactyly and
HPE, and, in a subset of patients, death within the 1st
year (Kelley et al. 1996; Jones 1997).
PATCHED-1, PATCHED-2, and SMOOTHENED
SHH functions by binding its 12-span transmem-
brane receptor proteins, PATCHED-1 (PTCH-1 [MIM
601309]) and PATCHED-2 (PTCH-2 [MIM 603673]),
in target cells (Stone et al. 1996; Smyth et al. 1999).
PATCHED-1 and, possibly, PATCHED-2, normally in-
hibit downstream signaling through a physical interac-
tion with a 7-span transmembrane protein, SMOOTH-
ENED (SMOH [MIM 601500]). In model systems in
which Shh is expressed nearby, it relieves the tonic in-
hibition of Smoothened by Patched and allows Shh-Ptch-
Gli signaling to progress (Murone et al. 1999).
Like all of the other components of the SHH-PTCH-
GLI pathway, the PATCHED and SMOOTHENED
genes are also clinically relevant. The PTCH gene func-
tions as a tumor suppressor, and activating SMOH mu-
tants have been shown to function as oncogenes (Stone
et al. 1996; Xie et al. 1998). Mutations of human PTCH-
1, PTCH-2, and SMOH have all been detected in bas-
al cell carcinomas and in medulloblastomas (MIM
155255) and result in dysregulated GLI signaling. Spo-
radic inactivating PTCH-1 mutations have also been
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Table 1
Human GLI Genes and Associated Diseases
Gene (Locus) Associated Human Disease(s) Presumed Mechanism(s)
GLI1 (12q13) Glioblastoma Amplification
Rhabdomyosarcoma Amplification
Osteosarcoma Amplification
B cell lymphoma Amplification
Basal cell carcinoma Misexpression
Predicts adult sarcoma grade Misexpression
GLI2 (2q14) Unknown Unknown
GLI3 (7p13) Greig cephalopolysyndactyly syndrome Deletion, point mutation, or translocation
Pallister-Hall syndrome Frameshift or nonsense mutation
Postaxial polydactyly type A Frameshift
Postaxial polydactyly type A/B Frameshift, nonsense, or missense mutation
Preaxial polydactyly type-IV Frameshift
GLI4 (HKR4)a (8q24.3 ) Unknown Unknown
a Gene encodes a Kru¨ppel-like protein and was named “GLI4” by the Human Gene Mapping Workshops.
reported in trichoepitheliomas (Vorechovsky et al.
1997), esophageal squamous cell carcinomas (Maesawa
et al. 1998 [MIM 133239]), and transitional cell car-
cinomas of the bladder (McGarvey et al. 1998 [MIM
109800]). Furthermore, PTCH-1–inactivating muta-
tions cause the genetic disease nevoid basal cell carci-
noma syndrome (NBCCS), also called “Gorlin syn-
drome” or “basal cell nevus syndrome” (BCNS [MIM
109400]), which is an autosomal dominant disorder
characterized by basal cell nevi with a high rate of ma-
lignant transformation, an increased risk of medullo-
blastomas and rhabdomyosarcomas, generalized over-
growth, and developmental defects including short
metacarpals, rib defects, broad facies, and dental ab-
normalities (Bale et al. 1991; Gorlin 1995; Jones 1997).
The GLI Family
The GLI1 gene was originally identified as an amplified
gene in a malignant glioma (Kinzler et al. 1987). It was
the first member described in the human GLI gene fam-
ily. During the past decade, four human genes have been
designated “GLI1”–“GLI4”, and these genes have been
mapped to separate loci by FISH (Arheden et al. 1989;
Ruppert et al. 1990; Kas et al. 1996; Matsumoto et al.
1996).
GLI1, GLI2, and GLI3 encode transcription factors
that share five highly conserved tandem C2-H2 zinc fin-
gers and a consensus histidine-cysteine linker sequence
between zinc fingers (Ruppert et al. 1988). These fea-
tures distinguish between the similar Gli and Kru¨ppel
protein families (Kinzler et al. 1988). The GLI1 and
GLI3 proteins recognize a conserved GACCACCCA se-
quence in the promoters of target genes (Kinzler and
Vogelstein 1990; Ruppert et al. 1990; Pavletich and
Pabo 1993; Vortkamp et al. 1995), and GLI2 recognizes
a nearly identical GAACCACCCA motif (Tanimura et
al. 1998). GLI4, which is also known as “HKR4” (hu-
man Kru¨ppel-related gene 4), is actually most similar
to the Drosophila Kru¨ppel family of zinc-finger proteins
(Ruppert et al. 1988) and was misclassified as a
member of the human GLI gene family (GLI4 [MIM
165280]) (Kas et al. 1996). This nomenclature issue has
caused confusion in the Gli literature during recent
years. Throughout the present report, the human GLI
family of genes refers to GLI1–GLI3. The chromoso-
mal locations of human GLI1–GLI4 are summarized
in table 1.
GLI1
In addition to its amplification in glioblastomas (Kinzler
et al. 1987), GLI1 has also been detected as an amplified
gene in some osteosarcomas, rhabdomyosarcomas, and
B cell lymphomas (Roberts et al. 1989; Werner et al.
1997), as shown in table 1. The clinical significance
of GLI1 amplification in tumors is unknown, since
the MDM2 (MIM 164785) and CDK4 (MIM 123829)
genes are usually coamplified. GLI1 is also overex-
pressed in basal cell carcinomas, compared with that in
normal human skin (Dahmane et al. 1997; Ghali et al.
1999). The degree of GLI1 overexpression (whether by
amplification or mutation) correlates with tumor grade
in adult bone and soft-tissue sarcomas (Stein et al. 1999).
GLI1 has been classified as an oncogene on the basis of
its ability to transform cells in cooperation with ade-
novirus E1A (Ruppert et al. 1991).
Expression of human GLI1 in transgenic mice results
in a range of developmental defects, including failure
to thrive and Hirschsprung-like dilatation of the gas-
trointestinal (GI) tract (Yang et al. 1997). The GI-tract
phenotype is consistent with endogenous mouse gli1
expression patterns (Walterhouse et al. 1993) and with
recent evidence that, in the mouse, Shh is responsible
for radial patterning of the intestine (Sukegawa et al.
2000).
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GLI2
Although no defects in GLI2 have been correlated, to
date, with human diseases, studies in mice suggest that
associations with basal cell carcinomas, skeletal defects,
and other disorders are likely (Sasaki et al. 1999;
Grachtchouk et al. 2000; Park et al. 2000).
GLI3
Mutations in human GLI3 have been implicated in
several types of birth defects. Translocations, deletions,
and point mutations throughout the GLI3 gene cause
Greig cephalopolysyndactyly syndrome (GCPS [MIM
175700]), which is characterized by syndactyly, predom-
inantly preaxial polydactyly, broad thumbs and first
toes, and facial anomalies such as hypertelorism and
frontal bossing (Vortkamp et al. 1991; Jones 1997; Wild
et al. 1997; Kalff-Suske et al. 1999). GLI3 frameshift
and nonsense mutations have also been linked to
Pallister-Hall syndrome (PHS [MIM 146510]), an au-
tosomal dominant disease involving hypothalamic ha-
martoma, central or postaxial polydactyly, syndactyly,
imperforate anus, anteverted nares and other facial ab-
normalities, and, occasionally, associated HPE and mal-
formations of the axial skeleton (Jones 1997; Kang et
al. 1997). Recently, frameshift, nonsense, and missense
GLI3 mutations were detected in the human polydactyly
syndromes postaxial polydactyly type A (PAPA [MIM
174200]), autosomal dominant preaxial polydactyly
type IV (MIM 174700), and postaxial polydactyly type
A/B (Radhakrishna et al. 1997, 1999). Contrary to early
reports, the type and location of GLI3 mutations do not
appear to correlate with clinical disease phenotype
(Kalff-Suske et al. 1999). Table 1 summarizes the GLI
family’s associations with human birth defects and
cancers.
Suppressor of Fused
Little is known, in human cells, about how information
gets from the cell surface to the human GLI proteins,
which are downstream effectors of SHH via PTCH and
SMOH (Sasaki et al. 1999). In the homologous Dro-
sophila system, this process involves the serine-threonine
kinase Fused (Fu), the kinesin-related protein Costal-2
(Cos-2), and a physical interaction with microtubules
(Robbins et al. 1997; Sisson et al. 1997). However, Cos-
2 and Fu have not yet been demonstrated in vertebrates.
The only cytoplasmic element that has been shown to
function upstream of the GLI genes in human cells is
Suppressor of Fused (Su[fu]), which cooperates with the
F-box–containing protein Slimb to inhibit transactiva-
tion by GLI1 (Stone et al. 1999). Su(fu) can inhibit SHH-
induced osteogenic differentiation and can sequester
GLI1 in the cytoplasm (Kogerman et al. 1999), but it is
currently unclear whether Su(fu) acts immediately down-
stream of PATCHED within the SHH pathway or,
rather, as an independent regulator of GLI-mediated sig-
naling. No human diseases have been associated, to date,
with defects in Su(fu).
CREB-Binding Protein (CBP)
Studies of human GLI3 protein have shown that it is
bound and coactivated by mouse CBP (MIM 600140),
which is a common transcriptional coactivator (Akimaru
et al. 1997; Dai et al. 1999). Several studies have shown
that human mutations leading to haploinsufficiency of
CBP cause Rubinstein-Taybi syndrome (RTS [MIM
180849]) (Petrij et al. 1995; Blough et al. 2000). Ru-
binstein-Taybi syndrome is a developmental disorder
with symptoms that include broad thumbs and first toes,
syndactyly, short stature, delayed osseous maturation,
vertebral anomalies, mental retardation, dysmorphic fa-
cies, cryptorchidism, and an increased risk of neural and
developmental tumors (Rubinstein 1990; Miller and Ru-
binstein 1995; Jones 1997). The similarity between the
Rubinstein-Taybi phenotype and diseases caused by
GLI3 mutations suggests that the biochemical interac-
tion between CBP and GLI3 may significantly influence
SHH signaling.
TWIST
A novel interaction between the SHH-PTCH-GLI
pathway and TWIST (MIM 601622), the developmen-
tal regulatory gene and potential oncogene (Gitelman
1997; Bourgeois et al. 1998; Maestro et al. 1999), has
been demonstrated (authors’ unpublished observation).
Mouse Twist protein can activate human GLI1 at the
transcriptional level by interacting with E-boxes in
GLI1’s first intron. Nonsense, missense, deletion, and
insertion mutations in several regions of the human
TWIST gene have been shown to cause Saethre-Chotzen
syndrome (SCS [MIM 101400]), an autosomal domi-
nant disease characterized by craniosynostosis, asym-
metrical facies, syndactyly, broad thumbs and first toes
with or without partial reduplication, ossification de-
fects, and prominent ear crura (El Ghouzzi et al. 1997;
Howard et al. 1997). Alternatively, some patients with
Saethre-Chotzen have TWIST mutations that appear to
disrupt either the stability of TWIST protein or its ability
to correctly localize to the nucleus (El Ghouzzi et al.
2000). The clinical phenotype of Saethre-Chotzen syn-
drome partially overlaps with those of other Shh-path-
way–related human diseases discussed above, indicating
that dysregulation of Gli-family transcription factors by
either Shh-signaling defects or TWIST mutations causes
similar downstream effects. It has not yet been deter-
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mined whether TWIST is regulated by SHH signaling,
but TWIST does appear to be linked to SHH signal
transduction.
GLI Research: Progress and Controversies
As the most downstream elements within the SHH-
PTCH-GLI signaling cascade, GLI proteins are the key
regulators of target-gene expression in response to SHH
signaling. Although it is known that the three GLI genes
encode zinc-finger transcription factors in the SHH-
PTCH-GLI pathway, there are many controversies and
unanswered questions.
There has been a great deal of discussion in recent
years as to whether the Gli proteins function as tran-
scriptional activators, repressors, or both. In several ex-
perimental systems, human GLI1 has been shown to
contain a VP16-like, C-terminal activation domain and
to be a transcriptional activator of both endogenous
genes such asHNF-3b (MIM 600288) and reporter con-
structs containing the GLI1 binding site. GLI1 repressor
function has never been observed (Lee et al. 1997; Yoon
et al. 1998; Dai et al. 1999).
Different groups have reported strong data suggesting
that GLI3 either activates (Dai et al. 1999) or represses
(Wang et al. 2000) GLI1 transcription or protein ac-
tivity. Human GLI3 appears to contain the C-terminal
activation domain, in addition to an N-terminal re-
pression domain, and can, in model systems, apparently
function as either an activator or repressor of down-
stream genes such as HNF-3b (Sasaki et al. 1999), Gli1,
and Ptch-1. The mechanism of switching between ac-
tivation and repression has not been unequivocally de-
termined, although cleavage of the GLI3 protein to
release activating or repressing fragments has been sug-
gested as one possibility. Current data suggest that hu-
man GLI2 works only as an activator, whereas mouse
gli2 can function as either an activator or a repressor
(Lee et al. 1997; Sasaki et al. 1997, 1999; Tanimura et
al. 1998; Dai et al. 1999; Ruiz i Altaba 1999; Shin et
al. 1999; von Mering and Basler 1999).
The homologue of GLI in Drosophila, cubitus in-
terruptus (ci), is localized in the cytoplasm, and its
translocation to the nucleus, where it functions as a
transcription factor, is part of the Hedgehog-signaling
response. The subcellular localization of Gli proteins
within the cell is a matter of debate. Immunohisto-
chemistry of several human tumor cell lines has dem-
onstrated GLI1 protein in both the nucleus and the cy-
toplasm, in varying proportions in different cell lines
(Stein et al. 1999). Other reports have noted GLI1 only
in the nucleus of Tera-1 and D259MG cells (Kinzler
and Vogelstein 1990) or mainly in the cytoplasm in
basal cell carcinomas (Ghali et al. 1999).
Nonhuman experimental systems have also been used
to study the localization of human GLI proteins, with
varying results. In transfection studies of monkey COS
cells, GLI1 accumulated primarily in the nucleus and,
to a limited extent, in the cytoplasm (Dahmane et al.
1997; Lee et al. 1997). However, in transfected 10T1/
2 mouse cells, human GLI1 localized primarily to the
cytoplasm, particularly in the presence of transfected
Su(fu) (Stone et al. 1999). GLI3 localization also dif-
fered between cell lines, with mainly cytoplasmic la-
beling in COS cells (Lee et al. 1997) and nuclear staining
in 10T1/2 cells (Ruiz i Altaba 1999). In one study, trans-
fected Hela cells showed full-length GLI3 in the cyto-
plasm, GLI3 with a PHS-type frameshift in the nucleus,
and GLI3 with a Greig syndrome–type frameshift in
both the cytoplasm and nucleus (Shin et al. 1999). It
has been suggested, on the basis of experiments with
mouse fibroblasts and frog tissues, that N-terminal GLI-
protein motifs target proteins to the nucleus, whereas
the C-terminal regions of GLI proteins contain a cy-
toplasmic tethering domain (Ruiz i Altaba 1999). The
discrepancies between these experiments may reflect dif-
ferences in localization of GLI that are based on dif-
ferent tissues or different cell-cycle states. Furthermore,
it is unclear whether the subcellular localization of Gli
proteins observed in nonhuman transfected cells accu-
rately reflects the subcellular localization of human GLI
in wild-type human cells and whether human tumor
cells localize GLI in the same manner as do wild-type
cells. Another unresolved issue in human GLI studies is
whether any of the GLI proteins are cleaved, since GLI’s
homologue in Drosophila, ci, requires cleavage into sep-
arate activator and repressor forms (Methot and Basler
1999).
There has been little convincing evidence to suggest
that human GLI1 is cleaved in vivo. GLI1 antibody has
demonstrated a major 150-kD band in human Tera-1
(teratocarcinoma) and human RMS (rhabdomyosar-
coma) cells and, independently, a single 150-kD band
in human D259 (glioblastoma) cells (Kinzler and Vo-
gelstein 1990; Ruppert et al. 1991). Mouse-embryo ex-
tracts have demonstrated a single gli1 protein band (Dai
et al. 1999), but frog gli1 has yielded multiple protein
bands when transfected into human cells (Ruiz i Altaba
1999).
Reports from different groups studying different cell
types have yielded conflicting data regarding GLI3. Hu-
man GLI3 transfected into 10T1/2 cells has produced
a single full-length band, whereas the same construct
transfected into COS cells has shown a full-length band,
as well as an ∼100-kD band (Ruiz i Altaba 1999). In
mouse cells, human GLI3 also produced a full-length
band at all times, but additional processed forms were
observed in the absence of Shh (Dai et al. 1999). Re-
cently, PKA-dependent cleavage of human GLI3 to an
83-kD form was reported in transfected COS, mouse
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limb, and chick limb cells, as well as in endogenous
mouse and chick limb buds. Phosphorylation of full-
length GLI3 was apparently necessary for cleavage. No
cleavage or phosphorylation of GLI2 was observed
(Wang et al. 2000).
Conclusions
Normal development is regulated by the complex inter-
action of gene hierarchies, and the central role of signal-
transduction pathways in these gene hierarchies is well
established. The Shh-Ptch-Gli pathway is one of the most
critical of these during early development. Although
some components and functions of the Shh-Ptch-Gli
pathway are highly conserved, the implications of spe-
cies-specific differences should not be overlooked. In hu-
mans, genetic disruption of SHH-PTCH-GLI–pathway
components leads to a range of developmental defects,
and aberrant SHH signaling in postnatal life leads to
dysregulated cell growth, as in basal cell carcinomas. As
such, study of the human SHH-PTCH-GLI pathway is
critical for the understanding of the pathogenesis of
SHH-related human diseases, as well as in the deter-
mination of potential therapeutic targets.
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